We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA OFFERS TIPS ON HANDLING BA, BE TESTING SAMPLES
FDA OFFERS TIPS ON HANDLING BA, BE TESTING SAMPLES
June 1, 2004
The FDA has issued a final guidance on how drugmakers, laboratories and others should handle reserve testing samples for bioavailabilty (BA) and bioequivalence (BE) studies used to support new and generic drug applications.